This trial is designed to assess the tolerability, safety, pharmacokinetic profile, and preliminary efficacy of the combination of ZGGS18 and ZG005 in patients with advanced solid tumors, including advanced cervical cancer, hepatocellular carcinoma, neuroendocrine cancer, and lung cancer.
Fully understand this study and voluntarily sign the ICF.
Age 18-75 years, no gender restriction.
Patients with advanced solid tumors who have failed standard treatment or are intolerant to standard treatment, as confirmed by histopathology or cytology.
Medical history, CT scan, or MRI indicates the presence of CNS metastases.
Other malignancies within 5 years.
Any other reason deeming the participant unsuitable for the study, as judged by the investigator.